Nonalcoholic Steatohepatitis

NASH-linked changes impact metformin pharmacokinetics

(HealthDay)—Nonalcoholic steatohepatitis (NASH)-associated changes in liver function affect kidney transporter expression and metformin pharmacokinetics, according to an experimental study published online May 27 in Diabetes ...

Jun 04, 2015
popularity6 comments 0

Non-alcoholic fatty liver disease (NAFLD) is one cause of a fatty liver, occurring when fat is deposited (steatosis) in the liver not due to excessive alcohol use. It is related to insulin resistance and the metabolic syndrome and may respond to treatments originally developed for other insulin-resistant states (e.g. diabetes mellitus type 2) such as weight loss, metformin and thiazolidinediones. Non-alcoholic steatohepatitis (NASH) is the most extreme form of NAFLD this being regarded as a major cause of cirrhosis of the liver of unknown cause.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Study examines the rise of plaque in arteries

The accumulation of cholesterol plaques in artery walls can lead to atherosclerosis, or the hardening of arteries that contributes to heart attacks and strokes. In a new study, Yale researchers investigate how plaque cells ...

Research could help fine-tune cancer treatment

Cancer therapies that cut off blood supply to a tumour could be more effective in combination with existing chemotherapeutic drugs—according to new research from the University of East Anglia.

Aggression neurons identified

High activity in a relatively poorly studied group of brain cells can be linked to aggressive behaviour in mice, a new study from Karolinska Institutet in Sweden shows. Using optogenetic techniques, the researchers were able ...